William Blair reports 9.7% Twist Bioscience (TWST) stake in 13G/A
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
William Blair Investment Management, LLC has filed Amendment No. 1 to a Schedule 13G reporting its ownership in Twist Bioscience Corp. As of the event date of 12/31/2025, the firm beneficially owned 5,954,429 shares of Twist Bioscience common stock, representing 9.7% of the outstanding class.
The filer reports sole voting power over 5,459,833 shares and sole dispositive power over 5,954,429 shares, with no shared voting or dispositive power. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of Twist Bioscience.
Positive
- None.
Negative
- None.
FAQ
What ownership stake in Twist Bioscience (TWST) does William Blair Investment Management report?
William Blair Investment Management, LLC reports beneficial ownership of 5,954,429 Twist Bioscience common shares, representing 9.7% of the class. This stake is disclosed in Amendment No. 1 to a Schedule 13G with an event date of December 31, 2025.
What type of SEC filing did William Blair make regarding Twist Bioscience (TWST)?
William Blair Investment Management, LLC filed Amendment No. 1 to a Schedule 13G for Twist Bioscience Corp. This filing reports passive beneficial ownership of the company’s common stock as of December 31, 2025, rather than seeking to influence control.
On what date is William Blair’s reported Twist Bioscience (TWST) ownership effective?
The reported ownership is tied to a date of event of December 31, 2025. As of that date, William Blair Investment Management, LLC beneficially owned 5,954,429 Twist Bioscience common shares, representing 9.7% of the company’s outstanding common stock class.
Does William Blair state an intent to influence control of Twist Bioscience (TWST)?
The filer certifies the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control of Twist Bioscience, other than activities solely in connection with a nomination under Rule 14a-11.
Who signed the Twist Bioscience (TWST) Schedule 13G/A on behalf of William Blair?
The Schedule 13G/A for Twist Bioscience was signed by Telmo Martins, Chief Compliance Officer of William Blair Investment Management, LLC. The signature block certifies that the information in the statement is true, complete, and correct as of February 9, 2026.